Evidence map›Paper›PMID 38664638›Full record

ArticleBMC complementary medicine and therapies2024

Ginsenoside compound K induces ferroptosis via the FOXO pathway in liver cancer cells.

Jiaxin Chen, Zhuoshi Wang, Jinghao Fu, Yuesong Cai, Haoyi Cheng, Xinmu Cui, Manqing Sun, Mingyue Liu, Xuewu Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Ginsenoside Rh4 Triggers Ferroptosis in Lung Cancer: TargetingInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiaxin ChenCollege of Medicine, Yanbian University, Yanji, China.
Zhuoshi WangCollege of Medicine, Yanbian University, Yanji, China.
Jinghao FuCollege of Medicine, Yanbian University, Yanji, China.
Yuesong CaiCollege of Medicine, Yanbian University, Yanji, China.
Haoyi ChengCollege of Medicine, Yanbian University, Yanji, China.
Xinmu CuiCollege of Medicine, Yanbian University, Yanji, China.
Manqing SunCollege of Medicine, Yanbian University, Yanji, China.
Mingyue LiuCollege of Medicine, Yanbian University, Yanji, China.
Xuewu ZhangCollege of Medicine, Yanbian University, Yanji, China. zhangxuewu@ybu.edu.cn.
Yanbian University · CN

Funding

the National Natural Science Foundation of China 82260783
6 · The paper itself

Abstract

Liver cancer is a common malignant tumor worldwide, traditional Chinese medicine is one of the treatment measures for liver cancer because of its good anti-tumor effects and fewer toxic side effects. Ginsenoside CK (CK) is an active component of ginseng. This study explored the mechanism by which CK induced ferroptosis in liver cancer cells. We found that CK inhibited the proliferation of HepG2 and SK-Hep-1 cells, induced ferroptosis of cells. Ferrostatin-1, an ferroptosis inhibitor, was used to verify the role of CK in inducing ferroptosis of liver cancer cells. Network pharmacological analysis identified the FOXO pathway as a potential mechanism of CK, and western blot showed that CK inhibited p-FOXO1. In cells treated with the FOXO1 inhibitor AS1842856, further verify the involvement of the FOXO pathway in regulating CK-induced ferroptosis in HepG2 and SK-Hep-1 cells. A HepG2 cell-transplanted tumor model was established in nude mice, and CK inhibited the growth of transplanted tumors in nude mice, p-FOXO1 was decreased in tumor tissues, and SLC7A11 and GPX4 expressions were also down-regulated after CK treatment. These findings suggested that CK induces ferroptosis in liver cancer cells by inhibiting FOXO1 phosphorylation and activating the FOXO signaling pathway, thus playing an antitumor role.

Indexed as

FerroptosisGinsenosidesLiver NeoplasmsMice, NudeSignal TransductionAnimalsCell Line, TumorForkhead Box Protein O1Hep G2 CellsHumansMiceMice, Inbred BALB CForkhead Box Protein O1ginsenoside compound KGinsenosidesAnticancerFerroptosisFOXO pathwayGinsenoside CKLiver cancer

Identifiers

PMID38664638
PMCPMC11044296
OpenAlexW4395463333

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.